MDNA Life Sciences will present at the Biotech Showcase 2016 to be held January 11-13, 2016, at the Parc 55 San Francisco.
Continue reading “MDNA Life Sciences to present at Biotech Showcase 2016”
News
MDNA Life Sciences reports positive results for its novel blood-based prostate cancer test
Performance measurements from the first phase of our ongoing two-part validation study for the Prostate Core Mitomic Test™ for prostate cancer yield positive results.
MDNA Life Sciences reports positive results from independent post-market study of Prostate Core Mitomic Test™
Our tissue-based Mitomic Prostate Core Test™ receives positive results from an independent post-market study conducted by the prestigious uro-oncology trials management organization, CUSP Group.
MDNA Life Sciences enters collaboration agreement with University of Cambridge to validate Mitochondrial Biomarker blood-based diagnostic for prostate cancer
The study will evaluate the Company’s novel mitochondrial DNA-based test for accurately identifying prostate cancer in blood samples from men with elevated PSA levels that are at risk for prostate cancer.
MDNA Life Sciences acquires Mitomic Technology
MDNA Life Sciences acquires Mitomic Technology and product pipeline.
Continue reading “MDNA Life Sciences acquires Mitomic Technology”